**SCREENING FOR ATRIAL FIBRILLATION: A REPORT OF THE AF-SCREEN INTERNATIONAL COLLABORATION**

**Ben Freedman** MBBS PhD FAHA1\*‡; John Camm MD2‡; HughCalkins MD3‡;Jeffrey S. Healey MD MSc4‡;Mårten Rosenqvist MD PhD5‡; Jiguang Wang MD PhD6‡; Christine M. Albert MD MPH7; Craig S. Anderson PhD8; Sotiris Antoniou BPharm(Hons) MSc9; Emelia J. Benjamin MD ScM FAHA10; Giuseppe Boriani MD PhD11; Johannes Brachmann MD PhD12; Axel Brandes MD DMSc13; Tze-Fan Chao MD PhD14; David Conen MD MPH15,4; Johan Engdahl MD PhD16; Laurent Fauchier MD PhD17; David A. Fitzmaurice MD18; Leif Friberg MD PhD19; Bernard J. Gersh MB,ChB DPhil20; David J. Gladstone MD PhD21; Taya V. Glotzer MD22; Kylie Gwynne MA23; Graeme J. Hankey MD24; Joseph Harbison MD25; Graham S. Hillis MBChB PhD26; Mellanie T. Hills BSc27; Hooman Kamel MD28; Paulus Kirchhof MD29; Peter R. Kowey30; Derk Krieger MD PhD31; Vivian WY Lee BSc PharmD32; Lars-Åke Levin PhD33; Gregory Y. H. Lip MD34; Trudie Lobban35; Nicole Lowres PhD36; Georges H. Mairesse MD37; Carlos Martinez MD MSc38; Lis Neubeck BA(Hons) PhD39; Jessica Orchard B.Ec/LLB MPH40; Jonathan P. Piccini MD MHS41; Katrina Poppe PhD42; Tatjana S. Potpara MD PhD43; Helmut Puererfellner MD44; Michiel Rienstra MD PhD45; Roopinder K. Sandhu MD MPH46; Renate B. Schnabel MD MSc47; Chung-Wah Siu MD48; Steven Steinhubl MD49; Jesper H. Svendsen MD DMSc50; Emma Svennberg MD PhD51; Sakis Themistoclakis MD52; Robert G. Tieleman MD PhD53; Mintu P. Turakhia MD MAS54; Arnljot Tveit MD PhD55; Steven B. Uittenbogaart MD MSc56; Isabelle C. Van Gelder MD PhD57; Atul Verma MD58; Rolf Wachter MD59; Bryan P. Yan MBBS60.

Word count: Text only: 5,021 words, abstract 301 words, 99 references

Affiliations:

1. Heart Research Institute, Charles Perkins Centre, and Concord Hospital Cardiology, University of Sydney, Australia
2. St Georges Hospital, London UK
3. Johns Hopkins University, Baltimore, USA
4. Population Health Research Institute, McMaster University, Hamilton, Canada
5. Karolinska Institute, Stockholm, Sweden
6. The Shanghai Institute of Hypertension, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China
7. Brigham and Womens Hospital, Harvard Medical School, Boston, USA
8. The George Institute for Global Health, Sydney, Australia
9. Barts Health NHS Trust, London, UK
10. NHLBI and Boston University’s Framingham Heart Study, Framingham, MA, USA
11. University of Modena and Reggio Emilia, Modena, Italy
12. Klinikum Coburg, Coburg, Germany
13. Odense University Hospital, Odense, Denmark
14. Cardiovascular Research Centre, National Yang-Ming University, Taipei, Taiwan
15. University Hospital, Basel, Switzerland
16. Karolinska Institute, Stockholm, Sweden
17. Université François Rabelais, Tours, France
18. University of Birmingham, Birmingham, UK
19. Karolinska Institute, Stockholm, Sweden
20. Mayo Clinic College of Medicine, Rochester, MN, USA
21. University of Toronto, Toronto, Canada
22. Hackensack University Medical Centre, Hackensack, USA
23. Poche Centre, University of Sydney, Sydney, Australia
24. University of Western Australia, Perth, Australia
25. Trinity College, Dublin, Ireland
26. Royal Perth Hospital, University of Western Australia, Perth, Australia
27. StopAfib.org, Dallas, USA
28. Weill Cornell Medical College, New York, USA
29. Institute of Cardiovascular Sciences, University of Birmingham, Birmingham UK; SWBH and UHB NHS trusts, Birmingham, UK; AFNET, Muenster, Germany
30. Lankenau Institute for Medical Research, Wynnewood, USA
31. University Hospital of Zurich, Zurich, Switzerland
32. Chinese University of Hong Kong, Hong Kong
33. University of Linköping, Linköping, Sweden
34. University of Birmingham, Birmingham, UK; and Aalborg University, Denmark
35. Arrhythmia Alliance, London, UK
36. Charles Perkins Centre, University of Sydney, Sydney, Australia
37. Cliniques du Sud Luxembourg, Arlon, Belgium
38. Institute for Epidemiology Statistics and Informatics, Frankfurt, Germany
39. Edinburgh Napier University, Edinburgh, UK
40. Charles Perkins Centre, University of Sydney, Sydney, Australia
41. Duke University, Durham, USA
42. University of Auckland, Auckland, New Zealand
43. University of Belgrade, Belgrade, Serbia
44. KH der Elisabethinen, Ordensklinikum Linz, Austria
45. University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands
46. University of Alberta, Edmonton, Canada
47. University Heart Centre, Hamburg, Germany
48. The University of Hong Kong, Hong Kong
49. Scripps Translational Science Institute, San Diego, USA
50. Rigshospitalet, The Heart Centre, University of Copenhagen, Copenhagen, Denmark.
51. Karolinska Institute, Stockholm, Sweden
52. Ospedale dell’Angelo Venice-Mestre, Venice, Italy
53. Martini Hospital, Groningen, the Netherlands
54. Stanford University, Stanford CA and VA Palo Alto Health Care System, Palo Alto, CA, USA
55. The Department of Medical Research, Bærum Hospital, Rud, Norway
56. Department of General Practice, Academic Medical Center, Amsterdam, the Netherlands
57. University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands
58. University of Toronto, Toronto, Canada
59. University of Göttingen, Göttingen, Germany
60. Chinese University of Hong Kong, Hong Kong

**\* Corresponding author** ‡ AF-SCREEN International Collaboration Steering Committee

**Address for correspondence:**

Professor Ben Freedman

Heart Research Institute, Charles Perkins Centre, Building D17, Level 3, Room 3114

The University of Sydney, NSW 2006, Australia

Email: [ben.freedman@sydney.edu.au](mailto:ben.freedman@sydney.edu.au)

# Abstract

Approximately 10% of ischemic strokes are associated with atrial fibrillation (AF) first diagnosed at the time of stroke. Detecting asymptomatic AF would provide an opportunity to prevent these strokes by instituting appropriate anticoagulation. The AF-SCREEN international collaboration was formed in September 2015, to promote discussion and research about AF screening as a strategy to reduce stroke and death, and to provide advocacy for implementation of country-specific AF screening programs. During 2016, 60 expert members of AF-SCREEN, including physicians, nurses, allied health professionals, health economists, and patient advocates were invited to prepare sections of a draft document. In August 2016, 51 members met in Rome to discuss the draft document, and consider the key points arising from it using a Delphi process. These key points emphasize that screen-detected AF found at a single-timepoint or by intermittent ECG recordings over 2 weeks is not a benign condition, and with additional stroke factors, carries sufficient risk of stroke to justify consideration of anticoagulation. With regard to the methods of mass screening, handheld ECG devices have the advantage of providing a verifiable ECG trace which guidelines require for AF diagnosis and would therefore be preferred as screening tools. Certain patient groups such as those with recent embolic stroke of uncertain source (ESUS) require more intensive monitoring for AF. Settings for screening include various venues both in the community and the clinic, but must be linked to a pathway for appropriate diagnosis and management for screening to be effective. It is recognized that health resources vary widely between countries and health systems, so the setting for AF screening should be both country- and health–system specific. Based on current knowledge, this white paper provides a strong case for AF screening now, while recognizing that large randomized outcomes studies would be helpful to strengthen the evidence base.

# AF-SCREEN: establishment and goals

AF-SCREEN international collaboration was founded in September 2015 and includes over 130 physicians (cardiologists, electrophysiologists, primary care physicians, stroke neurologists and geriatricians), nurses, allied health professionals, epidemiologists, health economists and patient group representatives from 32 countries. The collaboration seeks to promote discussion and research about screening for unknown or under-treated atrial fibrillation (AF) to reduce stroke and death, and to provide advocacy for implementation of country-specific AF screening programs ([www.af-screen-intcollab.org](http://www.af-screen-intcollab.org/), accessed Feb 28th 2017).

Although many with AF develop symptoms leading to appropriate diagnosis and management, the first manifestation may be a debilitating stroke or death. Finding AF before symptoms are manifested could lead to initiation of appropriate effective therapy including oral anticoagulants (OACs) to reduce stroke and death1, and potentially to initiation of risk-factor modifications to reduce complications from AF progression.

The past decade has witnessed a surge in the number and sophistication of diagnostic tools, ranging from inexpensive devices which detect persistent or paroxysmal AF, to devices capable of long-term continuous characterization of brief, asymptomatic AF. Those participating in the AF-SCREEN collaboration recognize a unique and timely opportunity to re-examine the approaches and rationale for AF diagnosis at an early asymptomatic stage. This prompted the development of a white paper on screening for AF, developed from a consensus meeting of AF-SCREEN members held in Rome in August 2016. Full details of the genesis of the white paper and the Delphi process used are provided in the online-only supplementary material (Pages 1-2 online appendix).

# Incidence of screen-detected AF and CIED (Cardiac Implantable Electronic Device)-detected Atrial High Rate Episodes

Many terms have been used to describe screen-detected AF, including unrecognized, undiagnosed, silent, subclinical AF (SCAF), and implanted cardiac device (CIED)-detected atrial high rate episodes. In this document we will refer to AF detected on single timepoint screening or patient-activated ECG recorders as ‘screen-detected AF’, while brief transient AF detected by CIEDs with atrial monitoring capability, are referred to as ‘CIED-detected atrial high rate episodes’. CIED-detected atrial high rate episodes could be due to oversensing, or other atrial tachyarrhythmias, and need close inspection of the stored electrograms before labeling them AF. CIEDs are not implanted to screen for AF, and CIED-detected atrial high rate episodes are not included in our definition of screen-detected AF, and should not be grouped with screen-detected AF. A full discussion on CIED-detected atrial high rate episodes has been included in this white paper principally to enhance our understanding of the significance of screen-detected AF and its relationship with stroke.

The incidence of screen-detected AF strongly depends on the population screened and duration/intensity of screening.2 Single timepoint screening of a general population aged ≥65 years detects undiagnosed AF in 1.4%,3 and the AF detected is largely persistent. In a large population-based study of individuals aged 75-76 years, a more intense 2-week screening program using twice-daily intermittent handheld ECG recordings identified AF in 3.0% (0.5% on the initial ECG4). The identical protocol restricted to those with at least 1 additional stroke risk factor identified 7.4% with AF.5

The incidence of atrial high rate episodes in patients with CIEDs ranges from 30-60% depending on the population and the detection algorithm used (Table 1).6-18  In 2,580 patients with a history of hypertension and no prior AF history, CIED-detected atrial high rate episodes ≥6 minutes were found in 35% of patients with implanted devices over a mean follow-up of 2.5 years and doubled the risk of stroke.11 Silent AF is more frequent than symptomatic AF in patients with a pacemaker or during external continuous rhythm monitoring.16 Because patients with CIEDs have a medical condition that may affect occurrence of atrial high rate episodes, other studies (ASSERT-II NCT01694394, REVEAL-AF NCT01727297, GRAF NCT01461434, Danish Loop study NCT02036450) using subcutaneous long-term continuous monitoring in people at risk of AF may provide a more reliable estimate of AF in non-CIED populations and elucidate its clinical significance. The initial report of the ASSERT-II study showed that brief episodes of subclinical AF are very common among individuals 65 years and older, who have stroke risk factors and evidence of left atrial enlargement. Among 256 patients with an average left atrial volume of 76.5 mL, receiving an implantable cardiac loop recorder, the rate of subclinical AF detection for AF episodes lasting at least 5 minutes was 34 % per year (presented at AHA Nov 2016).

# Risk of stroke and death in untreated screen-detected AF

There are no data which specifically address the risk of stroke and death in untreated screen-detected AF in the general population. The closest approximation are cohort studies of individuals with AF detected incidentally in the absence of symptoms. One study19 showed that individuals who were asymptomatic at presentation were three times as likely to have had an ischemic stroke prior to AF diagnosis, and in follow-up had similar risk of stroke and death as those with symptomatic AF. In a later study from this group, 161/476 individuals with new AF were asymptomatic at presentation, and these had an increased risk for cardiovascular (HR 3.12, 1.50-6.45) and all-cause mortality (HR 2.96, 1.89-4.64) compared to those with typical symptoms, after adjustment for CHA2DS2-VASc score and age (Figure 1).20

In 5555 patients with asymptomatic clinical AF detected incidentally in general practice, adjusted stroke rate in the 1460 untreated patients was 4% and all-cause mortality 7% over 1.5 years of follow-up, compared to 1% and 2.5% respectively in matched controls without AF.21, 22 In the EORP AF registry, mortality at 1 year was more than 2-fold higher in asymptomatic versus symptomatic AF (9.4% vs 4.2%, P < .0001).23 In the Belgrade AF study, survival free of AF progression or ischemic stroke was worse in those with an asymptomatic presentation.24

The major studies regarding thromboembolic risk of CIED-detected atrial high rate episodes in patients with implanted pacemakers, defibrillators, and cardiac re-synchronization devices are summarized in Table 2.6, 7, 9-11, 13, 17All show increased stroke rate with CIED-detected atrial high rate episodes, but the absolute risk of stroke was much lower than might be expected for patients with clinical AF and similar CHA2DS2-VASc score. A minimum of five minutes atrial high rate episodes was found to have clinical relevance in the MOST Study.10 Alternative arbitrary or data-derived atrial high rate episodes burden cut-points have been explored over the subsequent ten years, ranging from five minutes to 24 hours.11 but uncertainty remains about the minimum burden that increases thromboembolic risk. A recent re-evaluation of ASSERT indicated that stroke risk was increased only in patients with atrial high rate episodes duration ≥24 hours.25

**Key point 1:** Screen-detected AF as found on single timepoint screening, or intermittent 30 second recordings over 2 weeks, is not a benign condition, and with additional stroke risk factors, carries sufficient risk of stroke to justify consideration of screening and therapy to prevent stroke.

# Response to treatment of screen-detected AF

Screening for a particular disease implies that there is an effective therapy that improves outcomes. For AF, OACs have a major impact on reducing stroke, systemic embolism and all-cause mortality.27 The non-vitamin-K antagonist OACs (NOACs) further improve outcomes with less intracranial bleeding.28 It has been questioned whether screen-detected AF should prompt OAC treatment, and whether the response to treatment is the same as for symptomatic AF. An undetermined proportion of asymptomatic patients with incidentally-detected AF were included in the pivotal anticoagulant studies, but these have not been analyzed separately.27 There are no randomized controlled trials (RCTs), and it may be unethical to randomize patients with screen-detected AF to no therapy or an ineffective drug such as aspirin. The treatment decision for a given individual with screen-detected AF is determined by stroke risk factors (CHA2DS2-VASc score) according to guidelines, 1, 29 and by the duration of the AF episode in the case of CIED-detected atrial high rate episodes.

In the cohort study of 5,555 asymptomatic patients with AF detected incidentally in general practice, OAC therapy (n=2,492) compared to no antithrombotic therapy (n=1,460) was associated with significantly reduced adjusted risk of stroke from 4% to 1%, and death from 7% to 4% in only 1.5 years, suggesting that screen-detected AF may respond similarly.21, 22 Ongoing studies including ARTESiA (NCT01938248) and NOAH (NCT02618577) will help refine the benefit of NOAC in CIED-detected atrial high rate episodes and provide more information on the burden or duration of atrial high rate episodes that will benefit.

Screen-detected AF (single timepoint screening or patient-initiated recording) is likely to have the same response to OAC therapy as incidentally detected AF and symptomatic AF, with significant reduction in stroke and death. The absolute level of stroke risk for CIED-detected atrial high rate episodes may be lower than screen-detected AF and may modify the risk-benefit of OAC therapy. The burden threshold of CIED-detected atrial high rate episodes/CHA2DS2-VASc score associated with a positive risk-benefit ratio is under investigation.

# Role of AF in ischemic stroke

In stroke registries, at least a third of patients with ischemic stroke have either previously known30, 31 or newly-detected AF at the time of stroke.32 Stroke was the first manifestation of AF in over 25% of AF-related strokes.30 The association with AF is even higher if prolonged post-stroke external or implanted monitoring is performed.33, 34 In the Swedish Riks-Stroke register of over 94,000 ischemic strokes, approximately 9% were associated with previously unknown AF, and 20% with known but undertreated AF,30, 31 while in a global registry, 10% were due to previously unknown AF.35

Recent evidence from CIEDs raises questions about the temporal and mechanistic relationship between AF and stroke, and whether AF is necessary for left atrial thromboembolism to occur.9, 36-38 In several studies there does not seem to be a proximate temporal relationship between device-detected atrial high rate episodes and strokes, even though patients with atrial high rate episodes are at increased risk for stroke(Table 3).18, 36, 37 Only a small minority of patients with CIED-detected atrial high rate episodes who have a stroke experience the arrhythmia in the month prior to a stroke;9, 36 one-third had no atrial high rate episodes during approximately 1 year of rhythm monitoring before their stroke and only manifested atrial high rate episodes after their stroke.18, 36 Furthermore, multiple markers of abnormal atrial substrate have been associated with stroke independently of AF.39 In a small proportion of patients, however, there is a close proximate relationship between a daily atrial high rate episode burden ≥5.5h and stroke, with risk highest in the 5 days prior to stroke, falling to a non-significant increase in risk by 30 days prior to stroke (Figure 2), pointing to AF being a risk factor in these patients.40 A limitation of the CIED studies is small numbers of strokes, and usually, lack of adjudication as cardio-embolic.

Even short AF episodes can create a prothrombotic state that persists for some time after the episode. Furthermore, an atrial cardiomyopathy related to aging and systemic risk factors42 can lead to AF and/or atrial thromboembolism. Once AF develops, it impairs atrial function and secondarily leads to atrial remodeling, which in addition to flow abnormalities, further increases thromboembolic risk.42 Atrial cardiomyopathy as a cause of thromboembolism before AF could explain why a brief period of AF is associated with stroke months later, why many patients manifest AF for the first time after a stroke, and why one-third of strokes are currently of unknown cause. Advanced neuro-cardiac imaging and continuous monitoring may provide further insights into the pathophysiology in future.

Nevertheless, AF remains a very important risk marker as well as risk factor for stroke, with well documented efficacy of OAC for stroke prevention. Anticoagulated AF patients have residual stroke rates similar to matched individuals without AF, which underlines the efficacy of OACs in prevention of AF-related stroke.22 OACs remain underused in AF patients at risk of stroke: 30-50% of eligible AF patients not being given OAC, many mistreated with aspirin monotherapy, and the remainder not receiving any antithrombotic therapy. 30, 33, 43

It is likely that both unknown and undertreated AF contribute to a substantial proportion of all strokes, which could be prevented by screening strategies. Regarding the role of AF in stroke, it is likely that AF is both a risk factor and a strong risk marker for stroke.

# Which patients to screen?

In order for a screening program to be efficient, the screening technique must have a high positive predictive value using a low-risk tool at low cost. Screening yield depends on disease prevalence and diagnostic test performance. AF increases disproportionally in older adults, rendering age one of the best predictors of AF.44 The prevalence of AF below age 50 is negligible in most populations and may not justify screening in this group.44 The prevalence of AF differs by ethnicity; for example indigenous Australians have a higher burden of AF and higher risk at much younger ages than Europeans.45

If the screening procedure is inexpensive and easy to use, e.g. pulse palpation or single timepoint handheld devices,46, 47 screening can be non-selective and just age-based. A threshold ≥65 years (a CHA2DS2-VASc score of at least 1 in a male and 2 in a female) will detect undiagnosed AF in 1.4% in clinic or population settings,3 in which case European Society of Cardiology (ESC) guidelines recommend *that OAC be considered* (Class IIa); *OACs are recommended (Class I)* for a score of 2 in a male or 3 in a female.29 Opportunistic screening in all patients contacting the health system aged ≥65 has been adopted in the ESC AF guidelines, 29 but might be more efficient if an older age threshold is chosen or an additional stroke risk factor is required48. Superiority over a simple age-based criterion, however, needs to be proven.

Among individuals aged 75 in Sweden, a single ECG detected 0.5-1% with undiagnosed AF.4, 5 Adding 2 weeks of twice-daily patient-activated handheld ECG detected an additional 2.5% with undiagnosed AF,4 and 7.4% after enrichment with ≥1 additional stroke risk factor.5 Even more AF is detected with continuous recording via external or implanted devices (Table 1), but that technology is costly and may only be justified in populations at high risk and with sufficient yield from screening, e.g. older age plus additional risk factors, or embolic stroke of undetermined source (see below). Adding biomarkers (e.g. natriuretic peptides, high-sensitivity troponin) to existing clinical predictors may improve prediction of AF incidence.49, 50 However, there is marginal improvement in model discrimination and reclassification.

**Key Point 2**:

Single timepoint screening of people aged ≥65 in the clinic or community appears justified, based on yield of screening and likely cost-effectiveness. For those over age 75, or in younger age groups at high risk of AF or stroke, two weeks of twice-daily intermittent AF screening may be warranted.

# Ischemic Stroke and Embolic Stroke of Undetermined Source (ESUS)

RCTs and observational studies have established the effectiveness of post-stroke ECG monitoring for improving AF detection32, 51 (number needed to screen=8-14), with longer monitoring durations increasing AF detection probability. Post-stroke ECG monitoring is likely cost-effective.52, 53 However, RCTs have not been powered to assess the effect of prolonged ECG monitoring on stroke or mortality.

After an acute ischemic stroke/transient ischemic attack (TIA), in patients not known to have AF and without contraindications to OACs, a tiered AF ECG monitoring approach is advised. ESC guidelines recommend ≥ 72 hours ECG monitoring in all stroke survivors,29 but more research is required to identify non-ESUS subgroups benefitting most from more prolonged monitoring. Ongoing RCTs are exploring an alternative strategy of blanket NOAC therapy after limited negative Holter monitoring in ESUS (RE-SPECT ESUS NCT02239120, and NAVIGATE ESUS NCT02313909).

**Key Point 3:**

Long-term continuous rhythm monitoring using either external or implanted devices or extended intermittent patient-activated recordings may diagnose clinically important AF in individuals with recent ESUS.

# Overview of screening methods: (Table 4)54-63

Pulse palpation to assess pulse irregularity is a readily accessible method for screening in primary care, shown effective as a screening strategy in the SAFE study.64 It can also be used in the community, in both high and low-middle income countries, but has some limitations.54 In the clinic it is usually performed by physicians or nurses, while in the community non-physician health professionals and lay people can be trained to detect pulse irregularity. In routine primary care, the pulse is infrequently assessed. Cardiac auscultation can also detect AF, but is even less frequently performed in primary care.

Innovation in technology has produced new screening devices which improve feasibility and cost-effectiveness of widespread screening. These devices are recognized as valid for AF detection by the European Primary Care Cardiovascular Society, 65 and could be used to complement traditional screening by pulse palpation.

Oscillometric blood pressure monitors with an AF detection function based on pulse irregularity offer high sensitivity (92-100%) and specificity (90-97%), and are superior to pulse palpation.56, 60, 61 The devices can be used by health workers or patients, provide single timepoint or multiple patient-activated recordings and have been evaluated by health technology assessments.66 Finger photoplethysmography, using a smartphone camera and flash, has sensitivity 93% and specificity 98% for AF detection using proprietary algorithms with variable techniques to deal with ectopic beats.63, 67, 68 Similar algorithms are being built into smart-watches and fitness bands. The technology is attractive given the wide distribution of smartphones, but requires a noise-free trace for optimal performance. Ultimately, with all pulse-based detection systems, an ECG is required to confirm AF,1, 69 either 12-lead (current gold standard) or single-lead documenting P-waves.

A range of handheld devices produce diagnostic quality single-lead (L1) ECGs, most with automated algorithms more accurate than pulse palpation (sensitivity 94-99%, and specificity 92-97%).56, 57, 59, 70 These devices have been widely used for single timepoint AF screening.47, 57 Repeated handheld ECG recordings over 14-28 days have diagnostic accuracy equivalent to standard event recorders, superior to 12-lead ECG and 24-hour Holter for paroxysmal AF, 5, 59, 71 and have been used successfully in large scale AF screening studies.4, 5 While single lead ECGs may not always show P-waves, the advantages outweigh this limitation. The accepted arbitrary episode duration for defining AF is 30 seconds.

Continuous monitoring coupled with a diagnostic algorithm will detect paroxysmal AF more effectively than repeated patient-activated devices, though the prognostic significance of very brief episodes is uncertain. This can be accomplished by non-invasive devices, e.g. prolonged Holter monitoring, a wearable non-adhesive dry-electrode belt,72 or by a wearable-patch: feasible for 2-4 weeks73 and superior to 24-hour Holter.

The main disadvantages of prolonged external monitoring are skin irritation from electrodes/patches leading to reduced patient compliance, and the large amounts of data generated.

All devices with automated AF diagnostic algorithms require low-noise high-quality signals for optimal performance. This may be difficult when devices are given to patients or used in the community. High sensitivity is desirable, but there is a trade-off with lower specificity which can create much extra work and cost in verifying diagnoses with an ECG (if not recorded by the device).69 Device performance, therefore, must be tested in the setting where it will be used for screening to optimize performance.

**Key Point 4:** Mass screening or opportunistic screening for AF can be accomplished by pulse palpation; oscillometric (blood pressure) or photoplethysmographic (smartphone camera) devices; and handheld ECG devices providing a rhythm strip. Because ECG confirmation is mandated by guidelines for the diagnosis of AF, handheld ECG devices have the advantage of providing a verifiable ECG trace, and would therefore would be preferred as screening tools. Prolonged continuous ECG monitoring with external or subcutaneous recorders will diagnose more paroxysmal AF, but requires further evaluation: cost-effectiveness will be limited by expense, and detection of AF with lower absolute stroke risk.

# Settings for screening

There has been increasing interest recently in community screening in a number of countries.3-5, 74-77 Prospective studies have used pulse palpation, single or multi-lead ECG; and single timepoint or intermittent recordings, using systematic or opportunistic approaches across entire populations or age-specific strata of total populations, or defined populations in cohort studies. Screening has also been performed opportunistically in volunteers during annual events (e.g. Heart Rhythm Week in Belgium.75) The STROKESTOP study,4 invited half of the 75-76 year olds in two Swedish regions to attend screening, and 53% accepted, similar to the rate in the SAFE study.64 This was a stepped approach, with an initial single-lead ECG, followed by twice-daily intermittent patient-activated ECG recordings over a 2-week period in those without AF.

Pharmacies offer an attractive setting for community screening.47, 78 People ≥65 years with chronic conditions in many countries visit their community pharmacy every 1-3 months. AF screening with pulse check and smartphone-based ECG in Australian pharmacies was found to be feasible, cost-effective47 and well accepted.79 The major issue is ensuring referral and then treatment of detected individuals,78 so an established referral pathway is crucial.

Primary care is an ideal setting: in addition to regular primary care physician visits, there is nursing support for screening, and there is a direct link with the practitioner to prescribe OAC. There are two challenges: first is a sustainable strategy for detecting undiagnosed AF and second, providing adequate treatment for patients with known or newly discovered AF, as under-treatment is common.80

The SAFE study showed that opportunistic screening with pulse palpation in primary care was as effective as systematic 12-lead ECG screening in detecting undiagnosed AF in patients ≥65 years, and more cost-effective.64 While some guidelines recommend screening using pulse palpation, 29 pulse taking is not common practice.81 The new ESC guidelines have added ECG rhythm strip to the recommendation on pulse palpation for opportunistic screening.29 For scalability and sustainability, screening could be linked to existing workflow e.g. cardiovascular risk management programs or influenza vaccination.46, 57, 82-84 Computerized medical records linked to electronic decision support tools85 (e.g. AF SMART, ACTRN12616000850471),could provide prompts for regular screening, calculate stroke risk, and advise guideline-recommended therapy to assist workflow and treatment decisions.

In some countries, large generalist or specialized outpatient clinics provide an alternative setting to primary care for screening,86 but have similar issues with sustainable delivery of the screening intervention and subsequent treatment.

**Key Point 5**: The setting for AF screening needs to be individualized according to country-specific and health care system-specific requirements and resources and must be linked to a pathway for appropriate diagnosis and management for screening to be effective. Settings that have been used effectively include some that are community-based and others based in primary care, specialist practices, or general or specialist clinics. Primary care and outpatient clinics have the advantage of a direct link with treatment and a potentially sustainable workflow (see online Supplementary material for country-specific considerations).

# Health-economic assessments

Economic assessment of AF screening depends on a range of factors, including:

* rate of undiagnosed AF in the target population
* the difference in AF detection between the screening intervention and routine practice without screening
* stroke and mortality risk of the target population
* the expected reduction in stroke and mortality and increase in bleeding risk from OAC
* the cost of the screening methodology
* country-specific “willingness-to-pay” thresholds to avoid one stroke

In the first paper on health economic modelling for AF screening,87 both annual ECG screening and pulse palpation with confirmatory ECG were cost-effective in a Japanese population. Later, the SAFE study evaluated opportunistic versus systematic screening using pulse palpation followed by ECG 64, 88 and showed, using probabilistic sensitivity analyses, a 60% likelihood that opportunistic screening was cost-effective in both men and women. The Swedish STROKESTOP population screening study4 confirmed that ECG screening was likely to be cost-effective using a lifelong decision-analytic Markov model.89 Two other smaller studies evaluating smartphone ECG screening in community pharmacies47 (relying on estimated stroke and death rates and improvements with OAC treatment in incidentally-detected asymptomatic AF),21 and pulse checking in an influenza vaccination clinic90 also described cost-effectiveness. A simulation of direct medical costs in USA concluded that costs were greater in those with undiagnosed AF than for similar people without AF, justifying strategies to identify and treat undiagnosed AF. 91

Most recently, a study of lifetime costs and effects of a single handheld ECG screening of patients >65 during the annual influenza vaccination in the Netherlands82 found that screening would decrease overall costs by €764 (USD$939) and increase QALYs by 0.27 per patient. That is, AF screening for patients >65 during the influenza vaccination was likely to be cost-saving.

Reviews of systematic and opportunistic screening for AF detection AF92, 93 indicate that both were more cost-effective than routine practice for those ≥65, though this depends on method chosen, frequency of screening and age. For example, a formal Health Technology Assessment in Ireland considered a number of models and found costs per QALY varying between €792,619 (USD$ 936,902) for screening annually from age 55 to €8,037 (USD$9,500 for a single screening at age 75,94 but there are no data on the detection rate for annual or other frequencies of repeated screening. More data are required to compare cost-effectiveness of different screening interventions and the effect of different age cutoffs.

# Screening for under-treated known AF

Under-treatment exposes patients to a significant risk of fatal or disabling strokes. Population surveys95, 96 and registries indicate treatment remains suboptimal with large country differences.30 Population screening using a variety of techniques3, 4, 75 would identify under-treated patients and may provide an opportunity to refer to appropriate physicians or clinics to initiate OACs or to re-initiate OACs in those who have discontinued. 4, 29, 30

A prospective, Swedish population-based study found 9.5% of individuals (81/848) were known to have AF on a 12 lead ECG: 43% of these were not on OAC.5 Through the screening program, 52% of under-treated individuals had OAC initiated. A similar number of patients had known AF (9.3%) in the STROKESTOP study4 but only 22% were not on OAC. After cardiologist follow-up, more than half without contraindications commenced OAC therapy. This highlights the importance of future implementation research in which AF screening programs incorporate well-defined referral pathways and strategies for initiating OAC therapy, in both newly diagnosed and under-treated known AF.

# Patient preferences and advocacy

A large patient survey reported a majority of patients with persistent AF were in favor of AF screening with handheld ECGs (T. Lobban and M.T. Hills, written communication, September 2016). Patients also believed healthcare professionals needed to be better educated about AF symptoms.

The patient voice is as important as the clinician voice in driving change. Political advocacy from patients, caregivers and patient-led organizations has demonstrated the need for improved awareness, education and disease information.97, 98 Patient-led organizations can more effectively identify the challenges patients face, and engage policy makers to bring about change,97 leading to improved outcomes for patients and healthcare providers ([www.stopafib.org](http://www.stopafib.org), [www.heartrhythmalliance.org](http://www.heartrhythmalliance.org) ). Campaigns such as the Arrhythmia Alliance’s ‘Know Your Pulse’ campaign to screen for AF can be very successful in raising awareness and bringing about policy change.

Numerous governing bodies such as the National Institute for Health and Care Excellence (NICE, UK) and scientific organizations now seek the input of patients and patient organizations in developing clinical guidelines and scientific publications. 1, 29

Patients support screening to detect AF earlier. Increased education about AF for healthcare professionals is required, ensuring they respond to any reported patient symptoms. Public awareness campaigns will be helpful to educate people about checking their pulse and the benefits of OAC for preventing AF-related stroke. It will be beneficial for professional health organizations to work in partnership with professional patient-led organizations to drive AF education and detection programs, advocate for screening, and evidence-based treatment for those with diagnosed AF.

# Current guidelines

The ESC recommends opportunistic pulse-taking in all patients aged ≥65 years or in high risk subgroups, followed by an ECG if irregular, to allow timely AF detection.88 29 Pulse taking in practice is recommended by the National Institute for Health and Care Excellence (NICE, UK) guidelines, but only for symptoms. However, the new 2016 ESC guideline 29 also includes: an ECG rhythm strip as an alternative to pulse palpation; at least 72 hours ECG monitoring after TIAor stroke with additional longer term monitoring considered; and consideration of systematic screening in patients aged ≥75 or those at high stroke risk. An additional recommendation is to interrogate CIEDs for atrial high rate episodes and if detected, prompt further ECG monitoring to document AF before initiating therapy.

The ACC/AHA/HRS Guidelines1 make no recommendation on the topic of screening but do state that early detection and treatment of asymptomatic AF before the first complications occur is a recognized priority for the prevention of stroke.

Guidelines address specific subgroups where screening may be worthwhile, including high risk patients (e.g. post-stroke, >age 75), in whom prolonged monitoring is more likely to detect AF.

**Key Point 6:** There is a need to perform large randomized controlled studies using hard endpoints (including stroke/systemic embolism and death), of strategies for screening, to strengthen the evidence base to inform guidelines and national systematic screening strategies.

# Conclusions (Fig 3)

In older individuals with screen-detected AF, the absolute risk of ischemic stroke and death appears sufficient to justify consideration of treatment with OACs. Irregularity of the pulse is a simple way to screen for AF, but pulse palpation is seldom done in routine practice, and inexpensive screening devices are available. Because an ECG is required to confirm AF diagnosis, devices which provide a medical quality ECG trace have an advantage over pulse-based devices and would be preferred as screening tools. Single timepoint screening for AF appears justified based on yield and cost-effectiveness, and as a further step, two weeks of twice daily intermittent recordings may be justified in people aged 75 or older, or in other groups at high risk of AF or AF-related stroke. Patient differences will modulate the type and intensity of screening (e.g. ESUS requires higher intensity). The setting for screening is highly dependent on the health system in each country and needs to be individualized, but must crucially be linked to a pathway for appropriate diagnosis and management. While the WHO criteria for screening appear to be met99 and the evidence is strong for commencing screening efforts in many countries, one or more large and adequately powered randomized outcomes trials of a strategy of screening would strengthen the evidence for adoption of larger scale systematic screening programs for AF to reduce ischemic stroke/systemic embolism and death.

# Supplementary material (online only)

1. Process adopted by AF-SCREEN to achieve consensus
2. AF incidence and future projections
3. Consequences of undiagnosed AF other than stroke
4. Secondary AF
5. Table A: Arguments against screening for AF and responses.
6. Country by country plan of potential AF screening implementation specific to the health system.
7. AF Screening reference list

# Acknowledgement

We would like to acknowledge the important role of Ms Kimberley Begley in organization of the AF-SCREEN meeting, and supporting the steering committee in all the logistics.

# Funding

AF-SCREEN received funding for holding its meeting from: Bayer HealthCare, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Medtronic, C-SPIN (Canadian Stroke Prevention Intervention Network), Zenicor and iRhythm. The sponsors played no role in setting the agenda or the program for the meeting and played no role in this document.

**List of AF-SCREEN members other than co-authors who contributed to the individual country profiles and who participated in the Delphi process:**

Al Awwad, A; Al-Kalili, F; Berge, T; Breithardt, G; Bury, G; Caorsi, WR; Chan, NY; Chen, SA; Christophersen, I; Connolly, S; Crijns, H; Davis, S; Dixen, U; Doughty, R; Du, X; Ezekowitz, M; Fay, M; Frykman, V; Geanta, M; Gray, H; Grubb, N; Guerra, A; Halcox, J; Hatala, R; Heidbuchel, H; Jackson, R; Johnson, L; Kaab, S; Keane, K; Kim, YH; Kollios, G; Løchen, ML; Ma, C; Mant, J; Martinek, M; Marzona, I; Matsumoto, K; McManus, D; Moran, P; Naik, N; Ngarmukos, T; Prabhakaran, D; Reidpath, D; Ribeiro, A; Rudd, A; Savalieva, I; Schilling, R; Sinner, M; Stewart, S; Suwanwela, N; Takahashi, N; Topol, E; Ushiyama, S; Verbiest van Gurp, N; Walker, N; Wijeratne, T.

**Tables**

Table 1: Incidence of CIED-detected atrial high rate episodes (AHREs) in the population with cardiac implanted devices

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Year** | **Trial** | **Device Indication** | **Clinical Profile of Patients** | **Mean age** | **% male** | **LVEF%** | **Mean CHADS2** | **Follow-up** | **AF burden threshold** | **Incidence of AF** |
| 2002 | Gillis et al.8 | PPMs for sinus node disease | All | 70 ± 12 | 52% | N.A. | N.A. | 718 ± 383 days | >1 min | 157/231 (68%) |
| 2003 | Ancillary MOST 10 | PPMs for sinus node disease | All | Median 73 (68,81) for no AHRE  Median 75 (68,79) for AHRE detected | 45% | N.A. | N.A. | Median 27 months | >5 min | 156/312 (50%) |
| 2010 | TRENDS15 | PPMs and ICDs  All indications | History of prior stroke  No history of AF  No OAC use  ≥1 stroke risk factor | 72.8±9.9 for no AHRE  74.0±9.1 for AHRE detected | 63% for no AHRE  71% for AHRE detected | N.A. | 4.1±0.8 for no AHRE  4.2±0.8 for AHRE detected | Mean 1.4 years | >5 min | 45/163 (28%) |
| 2012 | TRENDS14 | PPMs and ICDs  All indications | No history of prior stroke  No history of AF  No OAC use  ≥1 stroke risk factor | 70.2± 11.8 | 66% | N.A. | ≥2 in 70% | 1.1 ± 0.7 years | >5 min | 416/1368 (30%) |
| 2012 | ASSERT11 | PPMs and ICDs  All indications | History of hypertension  No history of AF  No OAC use | 76±7 for no AHRE  77±7 for AHRE detected | 59% for no AHRE  56% for AHRE detected | N.A. | 2.3±1.0 for no AHRE  2.2±1.1 for AHRE detected | 2.5 years | >6 min | 895/2580 (34.7%) |
| 2012 | Home Monitor CRT17 | CRTDs and CRTPs  CHF | Heart failure  No history of AF | 66 ±10 | 77% | 25 (20–30) | ≥2 in 64% | 370 days (253-290) | ≥14 min | 126/560 (23%) |
| 2013 | Healey et al.12 | PPMs  All indications | All | 71.7 ±14.4 for no AHRE  74.3±13.7 for AHRE detected | 59% for no AHRE  58% for AHRE detected | N.A. | 2.02± 1.30 for no AHRE  2.23±1.47 for AHRE detected | Single center  Retrospective | >5 min | 246/445 (55.3%) |
| 2015 | IMPACT18 | ICDs and CRTDs  All indications | No permanent AF  No contra-indications for OAC | 64.2+11.5 for Control  64.7+10.8 for Intervention | 73% for Control  74% for Intervention | 29.4+11.3 for Control  29.9+10.8 for Intervention | 2 (median) | 701 days | >4-12 sec | 945/2718 (34.8%) |
| 2016 | RATE Registry 13 | PPMs and ICDs | All  No permanent AF, | 73.6±11.8 for PPMs,  64.5±12.6 for ICDs | 54% in PPM  72% in ICDs | 57.8±10.5 for PPM  29.2±11.3 for ICDs | 1.8±1.0 for PPM  2.0±0.8 for ICDs | 22.9 months (median) | > 3 atrial premature complexes | 145/300(48%) of PPM pts  155/300 (52%) of ICD pts  Of the representative samples studied |

**Legend:** PPM = permanent pacemaker; ICD = Implanted cardioverter defibrillator; AHREs = atrial high rate episodes

**Table 2: Summary of studies regarding CIED-detected** atrial high rate episodes **(AHREs) and thromboembolic risk**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Year** | **Trial** | **Number of patients** | **Duration of Follow-up** | **AF Burden Threshold** | **Atrial Rate Cutoff** | **AF Burden Threshold** | **Hazard Ratio for TE Event** | **TE Event Rate**  **(below vs. above AF burden threshold)** |
| 2003 | Ancillary MOST10 | 312 | 27 months  (median) | 5 minutes | >220 bpm | 5 minutes | 6.7 (p=0.020) | 3.2% overall  (1.3% vs. 5%) |
| 2005 | Italian AT500 Registry7 | 725 | 22 months  (median) | 24 hours | >174 bpm | 24 hours | 3.1 (p=0.044)  CI 1.1 to 10.5 | 1.2% annual rate |
| 2009 | Botto et al.6 | 568 | 1 year  (mean) | CHADS2+AF burden | >174 bpm | CHADS2+AF burden | n/a | 2.5% overall  (0.8% vs. 5%) |
| 2009 | TRENDS9 | 2486 | 1.4 years  (mean) | 5.5 hours | >175 bpm | 5.5 hours | 2.2 (p=0.060)  (0.96 to 5.05, p= 0.06) | 1.2% overall  (1.1% vs. 2.4%) |
| 2012 | Home Monitor CRT17 | 560 | 370 days  (median) | 3.8 hours | >180 bpm | 3.8 hours | 9.4 (p=0.006) (1.8–47, 0, p=0.006) | 2.0% overall |
| 2012 | ASSERT11 | 2580 | 2.5 years  (mean) | 6 minutes | >190 bpm | 6 minutes | 2.5 (p=0.007)  CI, 1.28 to 4.85 | (0.69% vs. 1.69%) |
| 2014 | SOS26 | 10016 | 2 years  (median) | 1 hour | >175 bpm | 1 hour | 2.11 (p=0.008)  CI: 1.22–3.64 | 0.39% per year  overall |
| 2016 | RATE Registry 13 | 5379  (3141 with pacemakers and 2238 with ICDs) | 22.9 months (median) | Non-sustained episodes of AHRE with a duration from 3 atrial premature complexes to 15-20 seconds | N.A. | Non-sustained episodes of AHRE with a duration from 3 atrial premature complexes to 15-20 seconds | HR 0.87 (95% CI 0.58–1.31, *p*=0.51) | For non-sustained episodes of AHRE :  0.55 (0.34–0.76) % per year for pacemakers and  0.81 (0.50–1.12) ) % per year for ICDs |

Legend TE = Thrombo-embolic

**Table 3: Temporal relationship between CIED-detected** atrial high rate episodes **(AHREs) and stroke**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Year** | **Trial** | **Number of patients with TE Event** | **Definition of AF episode** | **Any AF Detected Prior to TE Event** | **AF Detected only after TE Event** | **No AF in 30 Days Prior to TE Event** | **Any AF in 30 Days Prior to TE Event** |
| 2012 | Boriani et al41 | 33/3438 | 5 minutes | 21/33 (64%) | NA | 12/33 (67%) | 11/33 (33%) |
| 2011 | TRENDS9 | 40/2486 | 5 minutes | 20/40 (50%) | 6/40 (15%) | 29/40 (73%) | 11/40 (27%) |
| 2014 | ASSERT11, 36 | 51/2580 | 6 minutes | 18/51 (35%) | 8/51 (16%) | 47/51 (92%) | 4/51 (8%) |
| 2014 | IMPACT18 | 69/2718 | 36/48 atrial beats ≥200bpm | 20/69 (29%) | 9/69 (13%) | 65/69 (94%) | 4/69 (6%) |
| 2015 | Turakhia et al40 | 187/9850 | ≥ 5.5 hours or ≥ 6min on any day 120 days prior | 36/187 (19%) ≥ 5.5 hours  50/187 (26%) ≥ 6 min | N/A | N/A |  |

Table 4: Sensitivity and specificity of different methods of screening for AF

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Device** | **Method of interpretation** | **Sensitivity (%)** | **Specificity (%)** | **Reference** |
| Pulse palpation |  | 94 (84-97) | 72 (69-75) | Cooke et al., 200654 |
| *Handheld single-lead ECGs* | |  |  |  |
| AliveCor (Kardia) heart monitor | Algorithm only (based on presence of P wave and RR irregularity) | 98 (89-100) | 97 (93-99) | Lau et al., 201355 |
| Merlin ECG event recorder | Cardiologist interpretation | 93.9 | 90.1 | Kearley et al., 201456 |
| Mydiagnostick | Algorithm only (based on RR irregularity) | 94 (87–98) | 93 (85–97) | Tieleman et al., 201457  Vaes et al., 201458 |
| Omron HCG-801 | Algorithm only (based on RR irregularity) | 98.7 (93.2-100) | 76.2(73.3-78.9) | Kearley et al., 201456 |
| Omron HCG-801 | Cardiologist interpretation | 94.4 | 94.6 | Kearley et al., 201456 |
| Zenicor EKG | Cardiologist interpretation | 96 | 92 | Doliwa et al., 200959 |
| *Modified Blood pressure monitors* | |  |  |  |
| Microlife BPA 200 Plus | Algorithm only (based on pulse irregularity) | 92 | 97 | Marazzi et al., 201260 |
| Microlife BPA 200 | Algorithm only (based on pulse irregularity) | 97 (81.4-100) | 90 (83.8-94.2) | Wiesel et al., 201461 |
| Omron M6 | Algorithm only (based on pulse irregularity) | 100 | 94 | Marazzi et al., 201260 |
| Omron M6 comfort | Algorithm only (based on pulse irregularity) | 30  (15.4-49.1) | 97  (92.5-99.2) | Wiesel et al., 201461 |
| Microlife WatchBP | Algorithm only (based on pulse irregularity) | 94.9 (87.5-98.6) | 89.7 (87.5-91.6) | Kearley et al., 201456 |
| *Plethysmographs* | |  |  |  |
| Finger probe | Algorithm only (based on pulse irregularity) | 100 | 91.9 | Lewis et al., 201162 |
| iPhone photo-plethysmograph | Algorithm only (based on pulse irregularity) | 97.0 | 93.5 | ¶McManus et al., 201663 |

LEGEND: The comparator for all studies was 12-lead ECG (¶also used 3-lead telemetry).

# References

1. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Jr., Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2014;130:e270-271.

2. Arya A, Piorkowski C, Sommer P, Kottkamp H, Hindricks G. Clinical implications of various follow up strategies after catheter ablation of atrial fibrillation. *Pacing Clin Electrophysiol*. 2007;30:458-462.

3. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. *Thromb Haemost*. 2013;110:213-222.

4. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. *Circulation*. 2015;131:2176-2184.

5. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. *Circulation*. 2013;127:930-937.

6. Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Zolezzi F, Favale S, Molon G, Ricci R, Biffi M, Russo G, Vimercati M, Corbucci G, Boriani G. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. *J Cardiovasc Electrophysiol*. 2009;20:241-248.

7. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G, Ricci R, Favale S, Zolezzi F, Di Belardino N, Molon G, Drago F, Villani GQ, Mazzini E, Vimercati M, Grammatico A, Italian ATRI. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. *J Am Coll Cardiol*. 2005;46:1913-1920.

8. Gillis AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. *J Cardiovasc Electrophysiol*. 2002;13:542-547.

9. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. *Circ Arrhythm Electrophysiol*. 2009;2:474-480.

10. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA, Investigators M. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). *Circulation*. 2003;107:1614-1619.

11. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH, Investigators A. Subclinical atrial fibrillation and the risk of stroke. *N Engl J Med*. 2012;366:120-129.

12. Healey JS, Martin JL, Duncan A, Connolly SJ, Ha AH, Morillo CA, Nair GM, Eikelboom J, Divakaramenon S, Dokainish H. Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. *Can J Cardiol*. 2013;29:224-228.

13. Swiryn S, Orlov MV, Benditt DG, DiMarco JP, Lloyd-Jones DM, Karst E, Qu F, Slawsky MT, Turkel M, Waldo AL. Clinical Implications of Brief Device-Detected Atrial Tachyarrhythmias in a Cardiac Rhythm Management Device Population: Results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes. *Circulation*. 2016;134:1130-1140.

14. Ziegler PD, Glotzer TV, Daoud EG, Singer DE, Ezekowitz MD, Hoyt RH, Koehler JL, Coles J, Jr., Wyse DG. Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. *Am J Cardiol*. 2012;110:1309-1314.

15. Ziegler PD, Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Koehler JL, Hilker CE. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. *Stroke*. 2010;41:256-260.

16. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. *Circulation*. 1994;89:224-227.

17. Shanmugam N, Boerdlein A, Proff J, Ong P, Valencia O, Maier SK, Bauer WR, Paul V, Sack S. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. *Europace*.14:230-237.

18. Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, Ip J, Holcomb R, Akar JG, Halperin JL, Investigators I. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. *Eur Heart J*. 2015;36:1660-1668.

19. Tsang TS, Barnes ME, Pellikka PA, Gin K, Miyasaka Y, Seward JB, Gersh BJ. Silent atrial fibrillation in olmsted county: A community-based study. *Can J Cardiol*. 2011;27:S122.

20. Siontis K, Gersh B, Killian Jea. Typical, atypical and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. *Heart Rhythm*. 2016;0:1-7.

21. Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. *Thromb Haemost*. 2014;112:276-286.

22. Freedman B, Martinez C, Katholing A, Rietbrock S. Residual risk of stroke and death in anticoagulant-treated patients with atrial fibrillation. *JAMA Cardiol*. 2016;1:366-368.

23. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, Sinagra G, Petrescu L, Tavazzi L, Maggioni AP, Lip GY. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. *Am J Med*. 2015;128:509-518.e502.

24. Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. *Int J Cardiol*. 2013;168:4744-4749.

25. Van Gelder IC, Healey JS, Crijns H, Wang J, Hohnloser SH, Gold MR, Capucci A, Lau CP, Morillo CA, Hobbelt A, Rienstra M, Connolly S. Duration of Device-detected Subclinical Atrial Fibrillation and Occurrence of Stroke in ASSERT. *Eur Heart J*. 2016;in press.

26. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gasparini M, Lewalter T, Camm JA, Singer DE. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). *Eur Heart J*. 2014;35:508-516.

27. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007;146:857-867.

28. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*. 2014;383:955-962.

29. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC, Endorsed by the European Stroke Organisation (ESO). *Eur Heart J*. 2016;37:2893-2962.

30. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. *Lancet*. 2016;388:806-817.

31. Friberg L, Rosenqvist M, Lindgren A, Terent A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. *Stroke*. 2014;45:2599-2605.

32. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. *Stroke*. 2014;45:520-526.

33. Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. *Stroke*. 2009;40:235-240.

34. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J, Investigators CA. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med*. 2014;370:2478-2486.

35. Perera KS, Vanassche T, Bosch J, Swaminathan B, Mundl H, Giruparajah M, Barboza MA, O'Donnell MJ, Gomez-Schneider M, Hankey GJ, Yoon BW, Roxas A, Jr., Lavallee P, Sargento-Freitas J, Shamalov N, Brouns R, Gagliardi RJ, Kasner SE, Pieroni A, Vermehren P, Kitagawa K, Wang Y, Muir K, Coutinho JM, Connolly SJ, Hart RG. Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke: Embolic Stroke of Undetermined Source Global Registry. *Stroke*. 2016;47:2197-2202.

36. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, Van Gelder IC, Hohnloser SH, Carlson M, Fain E, Nakamya J, Mairesse GH, Halytska M, Deng WQ, Israel CW, Healey JS, Investigators A. Temporal relationship between subclinical atrial fibrillation and embolic events. *Circulation*. 2014;129:2094-2099.

37. Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, Ziegler PD, Investigators T. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. *Heart Rhythm*. 2011;8:1416-1423.

38. Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. *Stroke*. 2016;47:895-900.

39. Kamel H, O'Neal WT, Okin PM, Loehr LR, Alonso A, Soliman EZ. Electrocardiographic left atrial abnormality and stroke subtype in the Atherosclerosis Risk In Communities study. *Ann Neurol*. 2015;78:670-678.

40. Turakhia MP, Ziegler PD, Schmitt SK, Chang Y, Fan J, Than CT, Keung EK, Singer DE. Atrial fibrillation burden and short-term risk of stroke: case-crossover analysis of continuously recorded heart rhythm from cardiac electronic implanted devices. *Circ Arrhythm Electrophysiol*. 2015;8:1040-1047.

41. Boriani G, Santini M, Lunati M, Gasparini M, Proclemer A, Landolina M, Padeletti L, Botto GL, Capucci A, Bianchi S, Biffi M, Ricci RP, Vimercati M, Grammatico A, Lip GY. Improving thromboprophylaxis using atrial fibrillation diagnostic capabilities in implantable cardioverter-defibrillators: the multicentre Italian ANGELS of AF Project. *Circ Cardiovasc Qual Outcomes*. 2012;5:182-188.

42. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D'Avila A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R, Hindricks G, Ho SY, Hoit B, Jalife J, Kim YH, Lip GY, Ma CS, Marcus GM, Murray K, Nogami A, Sanders P, Uribe W, Van Wagoner D, Nattel S, Centurion OA, Kuck KH, Patton KK, Sapp JL, Stiles M, Svendsen JH, Upadhyay GA, Shantsila A. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: definition, characterization, and clinical implication. *Europace*. 2016;32:247-278.

43. Hsu JC, Maddox TM, Kennedy KF, Katz DF, Marzec LN, Lubitz SA, Gehi AK, Turakhia MP, Marcus GM. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: Insights from the NCDR pinnacle registry. *JAMA Cardiol*. 2016;1:55-62.

44. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim Y-H, McAnulty JH, Jr., Zheng Z-J, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJL. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation*. 2014;129:837-847.

45. Katzenellenbogen JM, Woods JA, Teng TH, Thompson SC. Atrial fibrillation in the Indigenous populations of Australia, Canada, New Zealand, and the United States: a systematic scoping review. *BMC Cardiovasc Disord*. 2015;15:87.

46. Kaasenbrood F, Hollander M, Rutten F, Gerhards L, Hoes A, Tieleman R. Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. *Europace*. 2016;18:1514-1520.

47. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, Bennett AA, Briffa T, Bauman A, Martinez C, Wallenhorst C, Lau JK, Brieger DB, Sy RW, Freedman SB. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. *Thromb Haemost*. 2014;111:1167-1176.

48. Benito L, Coll-Vinent B, Gómez E, Martí D, Mitjavila J, Torres F, Miró Ò, Sisó A, Mont L. EARLY: a pilot study on early diagnosis of atrial fibrillation in a primary healthcare centre. *Europace*. 2015;17:1688-1693.

49. Schnabel RB, Wild PS, Wilde S, Ojeda FM, Schulz A, Zeller T, Sinning CR, Kunde J, Lackner KJ, Munzel T, Blankenberg S. Multiple biomarkers and atrial fibrillation in the general population. *PLoS One*. 2014;9:e112486.

50. Sinner MF, Stepas KA, Moser CB, Krijthe BP, Aspelund T, Sotoodehnia N, Fontes JD, Janssens AC, Kronmal RA, Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA, Schnabel RB, Vasan RS, Wang TJ, Agarwal SK, McManus DD, Franco OH, Yin X, Larson MG, Burke GL, Launer LJ, Hofman A, Levy D, Gottdiener JS, Kaab S, Couper D, Harris TB, Astor BC, Ballantyne CM, Hoogeveen RC, Arai AE, Soliman EZ, Ellinor PT, Stricker BH, Gudnason V, Heckbert SR, Pencina MJ, Benjamin EJ, Alonso A. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. *Europace*. 2014;16:1426-1433.

51. Sposato LA, Cipriano LE, Saposnik G, Vargas ER, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol*. 2015;14:377-387.

52. Higgins P, MacFarlane PW, Dawson J, McInnes GT, Langhorne P, Lees KR. Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. *Stroke*.44:2525-2531.

53. Yong JH, Thavorn K, Hoch JS, Mamdani M, Thorpe KE, Dorian P, Sharma M, Laupacis A, Gladstone DJ. Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke. *Stroke*. 2016;47:2380-2385.

54. Cooke G, Doust J, Sanders S. Is pulse palpation helpful in detecting atrial fibrillation? A systematic review. *J Fam Pract*. 2006;55:130-134.

55. Lau J, Lowres N, Neubeck L, Brieger D, Sy R, Galloway C, Albert D, Freedman S. Performance of an Automated iPhone ECG Algorithm to Diagnose Atrial Fibrillation in a Community AF Screening Program (SEARCH-AF). *Heart Lung Circ*. 2013;22, Supplement 1:S205.

56. Kearley K, Selwood M, Van den Bruel A, Thompson M, Mant D, Hobbs FR, Fitzmaurice D, Heneghan C. Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors. *BMJ Open*. 2014;4:e004565.

57. Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, Hofman C, Houben RP. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. *Europace*. 2014;16:1291-1295.

58. Vaes B, Stalpaert S, Tavernier K, Thaels B, Lapeire D, Mullens W, Degryse J. The diagnostic accuracy of the MyDiagnostick to detect atrial fibrillation in primary care. *BMC Fam Pract*. 2014;15:113.

59. Doliwa PS, Frykman V, Rosenqvist M. Short-term ECG for out of hospital detection of silent atrial fibrillation episodes. *Scand Cardiovasc J*. 2009;43:163-168.

60. Marazzi G, Iellamo F, Volterrani M, Lombardo M, Pelliccia F, Righi D, Grieco F, Cacciotti L, Iaia L, Caminiti G, Rosano G. Comparison of Microlife BP A200 Plus and Omron M6 blood pressure monitors to detect atrial fibrillation in hypertensive patients.[Erratum appears in Adv Ther. 2014;31:1317]. *Adv Ther*. 2012;29:64-70.

61. Wiesel J, Arbesfeld B, Schechter D. Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. *Am J Cardiol*. 2014;114:1046-1048.

62. Lewis M, Parker D, Weston C, Bowes M. Screening for atrial fibrillation: sensitivity and specificity of a new methodology. *Br J Gen Pract*. 2011;61:38-39.

63. McManus DD, Chong JW, Soni A, Saczynski JS, Esa N, Napolitano C, Darling CE, Boyer E, Rosen RK, Floyd KC, Chon KH. PULSESMART: Pulse-Based Arrhythmia Discrimination Using a Novel Smartphone Application. *J Cardiovasc Electrophysiol*. 2016;27:51-57.

64. Fitzmaurice DA, Hobbs FDR, Jowett S, Mant J, Murray ET, Holder R, Raftery JP, Bryan S, Davies M, Lip GYH, Allan TF. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. *Br Med J (Clin Res Ed)*. 2007;335:383.

65. Hobbs FR, Taylor CJ, Jan Geersing G, Rutten FH, Brouwer JR. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. *Eur J Prev Cardiol*. 2016;23:460-473.

66. National-Institute-for-Health-and-Care-Excellence. Medical technology guidance: Watch BP Home A for diagnosing and monitoring hypertension and detecting atrial fibrillation. Available from: https://www.nice.org.uk/guidance/mtg13/documents/watchbp-home-a-for-diagnosing-and-monitoring-hypertension-and-detecting-atrial-fibrillation-assessment-report-overview2, accessed 2 September 2016.

67. McManus DD, Lee J, Maitas O, Esa N, Pidikiti R, Carlucci A, Harrington J, Mick E, Chon KH. A novel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation. *Heart Rhythm*. 2013;10:315-319.

68. Chan PH, Wong CK, Poh YC, Pun L, Leung WWC, Wong YF, Wong MMY, Poh MZ, Chu DWS, Siu CW. Diagnostic performance of a smartphone‐based photoplethysmographic application for atrial fibrillation screening in a primary care setting. *J Am Heart Assoc*. 2016;5:e003428.

69. Freedman B. Screening for Atrial Fibrillation Using a Smartphone: Is There an App for That? *J Am Heart Assoc*. 2016;5:e00400.

70. Lau JK, Lowres N, Neubeck L, Brieger DB, Sy RW, Galloway CD, Albert DE, Freedman SB. iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. *Int J Cardiol*. 2013;165:193-194.

71. Hendrikx T, Rosenqvist M, Wester P, Sandstrom H, Hornsten R. Intermittent short ECG recording is more effective than 24-hour Holter ECG in detection of arrhythmias. *BMC Cardiovasc Disord*. 2014;14:41.

72. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O'Donnell M, Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M, Investigators E, Coordinators. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med*. 2014;370:2467-2477.

73. Turakhia MP, Ullal AJ, Hoang DD, Than CT, Miller JD, Friday KJ, Perez MV, Freeman JV, Wang PJ, Heidenreich PA. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). *Clin Cardiol*. 2015;38:285-292.

74. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, Stijnen T, Lip GYH, Witteman JCM. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *Eur Heart J*. 2006;27:949-953.

75. Proietti M, Mairesse GH, Goethals P, Scavee C, Vijgen J, Blankoff I, Vandekerckhove Y, Lip GY. A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. *Europace*. 2016:euw069.

76. Tveit A, Abdelnoor M, Enger S, Smith P. Atrial fibrillation and antithrombotic therapy in a 75-year-old population. *Cardiology*. 2008;109:258-262.

77. Uittenbogaart SB, Verbiest-van Gurp N, Erkens PM, Lucassen WA, Knottnerus JA, Winkens B, van Weert HC, Stoffers HE. Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial. *Trials*. 2015;16:478.

78. Sandhu RK, Dolovich L, Deif B, Barake W, Agarwal G, Grinvalds A, Lim T, Quinn FR, Gladstone D, Conen D, Connolly SJ, Healey JS. High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. *Open Heart*. 2016;3:e000515.

79. Lowres N, Krass I, Neubeck L, Redfern J, McLachlan A, Bennett A, Freedman SB. Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. *Int J Clin Pharm*. 2015;12:350-360.

80. Proietti M, Nobili A, Raparelli V, Napoleone L, Mannucci PM, Lip GY, investigators R. Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. *Clin Res Cardiol*. 2016;105:912-920.

81. Willits I, Keltie K, Craig J, Sims A. WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension: a NICE Medical Technology Guidance. *Appl Health Econ Health Policy*. 2014;12:255-265.

82. Jacobs M, Kaasenbrood F, Postma M, van Hulst M, Tieleman RG. Cost-effectiveness of screening for atrial fibrillation in primary care with a hand-held, single-lead ECG device in the Netherlands. *Europace*. 2016:pii: euw285. [Epub ahead of print].

83. Lowres N, Neubeck L, Freedman SB. Can screening for atrial fibrillation be implemented at scale? *Europace*. 2016;18:1449-1451.

84. Orchard J, Lowres N, Freedman B, Ladak L, Lee W, Zwar N, Peiris D, Kamaladasa Y, Li J, Neubeck L. Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): A feasibility study. *Eur J Prev Cardiol.* 2016;23:suppl 13-20.

85. Eckman MH, Lip GY, Wise RE, Speer B, Sullivan M, Walker N, Kissela B, Flaherty ML, Kleindorfer D, Baker P. Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation. *Am Heart J*. 2016;176:17-27.

86. Yan B, Chan L, Lee V, Freedman B. Medical outpatient clinics an ideal setting for atrial fibrillation screening using a handheld single-lead ECG with automated diagnosis. *Eur Heart J*. 2016;37:888.

87. Maeda K, Shimbo T, Fukui T. Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan. *J Med Screen*. 2004;11:97-102.

88. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. *Health Technol Assess*. 2005;9:iii-iv, ix-x, 1-74.

89. Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L, Frykman-Kull V, Levin LA. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. *Europace*. 2015;17:1023-1029.

90. Rhys GC, Azhar MF, Foster A. Screening for atrial fibrillation in patients aged 65 years or over attending annual flu vaccination clinics at a single general practice. *Qual Prim Care*. 2013;21:131-140.

91. Turakhia MP, Shafrin J, Bognar K, Goldman DP, Mendys PM, Abdulsattar Y, Wiederkehr D, Trocio J. Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States. *Am J Cardiol*. 2015;116:733-739.

92. Moran PS, Teljeur C, Ryan M, Smith SM. Systematic screening for the detection of atrial fibrillation. *Cochrane Database Syst Rev*. 2016;6:Cd009586.

93. Health Information and Quality Authority. Health technology assessment (HTA) of a national screening programme for atrial fibrillation in primary care. 2015;2016

94. Smyth B, Marsden P, Corcoran R, Walsh R, Brennan C, McSharry K, Clarke J, Kelly PJ, Harbison J. Opportunistic screening for atrial fibrillation in a rural area. *QJM*. 2016;109:539-543.

95. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. *J Intern Med*. 2013;274:461-468.

96. Schnabel RB, Wilde S, Wild PS, Munzel T, Blankenberg S. Atrial fibrillation: its prevalence and risk factor profile in the German general population. *Dtsch Arztebl Int*. 2012;109:293-299.

97. Lobban TC, Camm AJ. Patient associations as stakeholders: a valuable partner for facilitating access to therapy. *Europace*. 2011;13 Suppl 2:ii21-24.

98. Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA, Hills MT, Hylek EM, LaHaye SA, Lip GY, Lobban T, Mandrola J, McCabe PJ, Pedersen SS, Pisters R, Stewart S, Wood K, Potpara TS, Gorenek B, Conti JB, Keegan R, Power S, Hendriks J, Ritter P, Calkins H, Violi F, Hurwitz J. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). *Europace*. 2015;17:1747-1769.

99. Freedman BS, Lowres N. Asymptomatic Atrial Fibrillation: The Case for Screening to Prevent Stroke. *JAMA*. 2015;314:1911-1912.


# Figures

Figure 1: Survival stratified by type of AF presentation (with permission from Siontis et al, Heart Rhythm 201620)




Legend: Kaplan-Meier curve for all-cause mortality according to presentation with either typical AF symptoms (palpitations with or without other symptoms), atypical symptoms (fatigue, chest pain, shortness of breath, lightheadedness, syncope, decreased exercise tolerance, but without palpitations) or asymptomatic (AF detected incidentally during a routine visit for an unrelated problem).

Figure 2: Time trend of risk of stroke for AF in 60 days prior to stroke (with permission From Turakhia et al, Circ Arrhythm Electrophysiol 201540)



**Legend:** Odds ratio for non-overlapping 5-day epochs of AF burden in implanted devices ≥5.5h in one day during the 5-day epoch, from 1-5 days before stroke (left-hand point) through 56-60 days before stroke (right-hand point). Each stroke case epoch is matched to six 5-day control epochs between 91- 120 days prior to stroke. There is a progressive fall in odds ratio of stroke from 17.4 for AF occurring 1-5 days before stroke, to non-significant increases for AF more than 21 days prior to stroke.

Figure 3: Diagrammatic representation of key points on screening



**Legend:** BP = blood pressure; PPG = photoplethysmography; enrichment = use of additional risk factors or biomarkers to either increase the proportion with unknown AF in the screened population, or increase the risk of stroke in those with AF detected by screening in that population; patients who are undertreated = patients with known AF who are not receiving oral anticoagulant according to guidelines, (see Page XXX section on “Should screening include undertreated known AF”). While this is not strictly speaking screening, such patients will be detected by population screening for AF, so this has been placed in a different shape with a dotted line connector; ESUS = embolic stroke of uncertain source.

**COI Disclosure statements**

B Freedman reports speakers fees and advisory board honoraria from Bayer Pharma AG (significant), Boehringer Ingelheim (modest), BMS/Pfizer (significant).

J Camm reports grants and personal fees from Bayer, Beorhinger Ingelheim and Daichi Sankyo, and personal fees from Pfizer/BMS.

H Calkins reports a consultancy with BMS/Pfizer (modest), speaker fees (significant) from Boehringer Ingelheim, and speaker fees and a consultancy with Medtronic (significant). He has also participated in a multicenter trial supported by Boerhringer Ingelheim (significant) J Healey reports grants from Medtronic, grants from Bristol-Meyers-Squibb, grants from Bayer, grants from Boehringer-Ingelheim, outside the submitted work.

M Rosenqvist reports grants (significant) and personal fees ( modetst) from Bayer, grants (significant) and personal ( modest) fees from Boehringer-Ingelheim, grants (significant) and personal fees ( modest) from BMS, grants and personal fees ( modest) from Pfizer, grants (modest) and personal fees ( modest)from Medtronic, grants (significant) and personal fees Significant) from St Jude Medical, grants and personal fees( modest) from Zenicor, personal fees (modest) from Sanofi, grants (significant) from Roche, outside the submitted work.

J Wang has no disclosures.

C Albert has no disclosures.

C Anderson reports personal fees from Boehringer Ingleheim, personal fees from Takeda China, personal fees from Astra Zeneca, personal fees from Medtronic, outside the submitted work; .

S Antoniou reports modest honoraria from Bayer, Boehringer Ingelheim, Pfizer/BMS and Daiichi Sankyo.

EJ Benjamin reports grants from NIH, grants from NIH/AHA, during the conduct of the study; other from American Heart Association, other from NIH/NCBI, outside the submitted work

G Boriani reports modest honoraria (as speaking fees) from Medtronic and Boston Scientific.

J Brachmann reports modest research grants and modest honoraria from: Medtronic, Bayer and Biotronik.

A Brandes has no disclosures.

TF Chao has no disclosures.

D Conen reports grants and personal fees from Bayer , grants and personal fees from Daiichi-Sankyo, grants from BMS/Pfizer, personal fees from Boehringer-Ingelheim, outside the submitted work

J Engdahl reports a significant research grant from Boehringer Ingelheim and modest honoraria from: Pfizer, Bristol Myers Squibb, Roche, Boehringer Ingelheim, Bayer and Sanofi.

L Fauchier reports a research grant from Bayer (significant); expert witness fees from: Bayer (significant), BMS/Pfizer (modest), Boehringer Ingelheim (significant), Medtronic (modest) and Novartis (modest); and honoraria from: Bayer (modest), BMS/Pfizer (modest), Boehringher Ingelheim (modest) and Daiichi Sankyo (modest).

D Fitzmaurice has no disclosures.

L Friberg reports substantial consultancy fees from Bayer, Boehringer-Ingelheim and Pfizer/BMS and substantial consultancy fees for participation in a European post authorization safety program (PASS) for rivaroxaban in response to a demand from the European Medicines Agency (EMA).

B Gersh reports consultancies (modest) for Janssen Pharmaceuticals, Boston Scientific, Medtronic and CIPLA pharmaceuticals.

D Gladstone reports personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Bristol-Myers Squibb, personal fees from Pfizer, outside the submitted work; and PI, EMBRACE trial; PI, SCREEN-AF trial; co-PI, PIAAF-FP study.

T Glotzer reports modest speaking honorarium from Medtronic.

K Gwynne has no disclosures.

G Hankey has received modest honoraria from Bayer for speaking at sponsored scientific symposia about stroke prevention in atrial fibrillation.

J Harbison has no disclosures.

G Hillis reports a significant grant from the Heart Foundation of Australia.

MT Hills has no disclosures.

H Kamel reports receiving lecture fees from Genentech on the topic of alteplase for acute ischemic stroke, and serving as an unpaid consultant to Medtronic and iRhythm on the subject of post-stroke heart-rhythm monitoring.

P Kirchhof reports grants from several public funding bodies, including EU grant agreement No 633196 [CATCH ME], British Heart Foundation (FS/13/43/30324), and Leducq Foundation, grants and personal fees from several industry companies involved producing AF therapies, grants and personal fees from ESC, AFNET, and other professional societies, outside the submitted work; In addition, P Kirchhof has a patent AF therapy pending to University of Birmingham, and a patent Markers for AF pending to University of Birmingham.

P Kowey reports moderate consultant fees from Medtronic and has significant equity in Cardionet.

D Krieger has no disclosures.

V Lee has no disclosures.

L Levin reports grants and personal fees from Boeringer Ingelheim, personal fees from Pfizer, personal fees from Bayer, outside the submitted work

GYH Lip reports significant consultancies for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo; significant speaker fees for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo.

T Lobban has no disclosures.

N Lowres has no disclosures.

G Mairesse reports grants and personal fees from Boehringer Ingelheim, grants from St Jude Médical, grants from Sanofi, outside the submitted work.

C Martinez has no disclosures .

L Neubeck reports grants (significant) from Pfizer/BMS and Bayer and honoraria (modest) from Pfizer/BMS, Bayer and Boehringer Ingelheim.

J Orchard has no disclosures.

J Piccini receives grants for clinical research from Abbott, Boston Scientific, Gilead, JNJ, the NHLBI, and Spectranetics and serves as a consultant to Allergan, Amgen, GSK, JNJ, Medtronic, Quest Labs, and Spectranetics

K Poppe has no disclosures.

T Potpara has no disclosures.

H Puererfellner reports modest honoraria and expert witness fees from: Medtronic, Saint Jude Medical and Biosense-Webster; and modest honoraria from Boehringer-Ingelheim, Bayer, Daiichi-Sankyo and Bristol-Myers-Squibb.

M Rienstra reports significant research grants from the Netherlands Organisation of Scientific Research and the Netherlands Cardiovascular Research Initiative supported by Dutch Heart Foundation.

R Sandhu has no disclosures.

R Schnabel reports funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 648131) and German Ministry of Research and Education (BMBF 01ZX1408A).

CW Siu ​​ has been on the speakers of symposia for Bayer, BMS/Pfizer, and Boehringer Ingelheim (modest).

S Steinhubl reports a significant research grant from Janssen Pharmaceutical.

JH Svendsen reports research grant (significant) and honoraria (modest) from Medtronic; research grants (modest) and honoraria (modest) from Biotronik, honoraria (modest) from Gilead, honoraria (modest) from Boehringer Ingelheim, honoraria (modest) from Astra-Zeneca and honoraria (modest) from Bayer.

E Svennberg has received modest honoraria from Merck Sharp & Dohme, Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Bayer and Sanofi, and a research grant from Roche (significant).  S Themistoclakis has no disclosures.

R Tieleman has a patent as co-inventor of the MyDiagnostick with modest royalties paid.

M Turakhia reports grants (>$10K) and personal fees ($<10K) from Medtronic, grants from Janssen (>$10K), personal fees from AliveCor (<$10K), personal fees from Daiichi Sankyo (<$10K), personal fees from Armetheon (<$10K), personal fees from St Jude Medical (>$10K), outside the submitted work.

A Tveit has no disclosures.

S Uittenbogaart has no disclosures.

I Van Gelder has no disclosures.

A Verma reports grants from Medtronic, outside the submitted work; .

R Wachter reports a significant research grant from Boehringer Ingelheim and modes honoraria from: Boehringer Ingelheim, Bayer, Bristol-Myers-Squibb, Medtronic and Pfizer.

BP Yan reports modest "other research support" in terms of AliveCor and Cardiio (Cardiio Inc, Cambridge, MA) devices.